Form D · Biotechnology
Immunologix, Inc.
Charleston, SC · CIK 0001488257
Offering snapshot reported Jul 20, 2011 · SEC filing
- Reported sold
- $251K Offering amount: $1.13M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 15, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 20, 2011 | Initial | $250,948 | No comparison | 7 | SEC filing |
| Aug 13, 2010 | Amendment | $1,090,168 | $892,668vs Apr 1, 2010 | 21 | SEC filing |
| Apr 1, 2010 | Initial | $197,500 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-163167
Source: Form D, filed Jul 20, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Bartosh | Director |
| Douglas M. Carnes | Director, Executive |
| Ryan N. Fiorini | Director, Executive |
| Robert Kennedy | Director |
| Richard A. Mc Gregor | Director |
| Lloyd A. Pearson | Director, Executive |
| Sam Tetlow | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
645 Meeting Street, Suite 8
Charleston, SC, 29403
Charleston, SC, 29403